Molecular Mechanisms and Therapies of Myeloid Leukaemia 3.0

Dear Colleagues,

Acute myeloid leukaemia (AML) is the second most frequent haematological malignancy in the paediatric population and remains a leading cause of childhood cancer mortality. In adults, AML is rare, increasing in incidence with age, but it is still the most common form of acute leukaemia. Paediatric AML is viewed as a separate disease to adult AML, thought to occur due to single genetic changes that alone are enough to cause AML at a young age. In adults, it has been thought that a lifetime accumulation of genetic alterations leads to the development of disease in later life. In both patient groups, and despite improvements of patient outcomes and the associated overall survival (OS) rates they offer, current therapies still have their limitations. It is essential, therefore, that we continue to identify new targets for therapies so that we can widen the scope of future treatments and determine their relevance to paediatric and adult leukaemia.

This Special Issue will focus on the identification and characterisation of the molecular mechanisms that underly AML pathogenesis and new targets for the therapy of this rare and heterogenous disease. The aim of this Special Issue is to review state-of-the-art research and look beyond current therapies to see where the future of AML treatment may reside.

Dr. Giovanni Martinelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute leukaemia
• myeloid leukaemia
• paediatric leukaemia
• adult leukaemia
• targeted therapy
• antigens